Search research articles
Contact Us
Filters
Showing results (111-120 of 141) with videos related to
Page
of 15
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 15, 2021
Prevalence and Landscape of Actionable Genomic Alterations in Renal Cell Carcinoma
Kyrollis Attalla, Renzo G DiNatale, Phillip M Rappold, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 10, 2022
Telaglenastat Plus Cabozantinib or Everolimus for Advanced or Metastatic Renal Cell Carcinoma: An Open-Label Phase I Trial
Funda Meric-Bernstam, Nizar M Tannir, Othon Iliopoulos, et al.
European Urology Focus
|
March 2, 2023
Cytoreductive Nephrectomy for Patients with Metastatic Sarcomatoid and/or Rhabdoid Renal Cell Carcinoma Treated with Immune Checkpoint Therapy
Andrew W Hahn, Ritesh R Kotecha, Paul V Viscuse, et al.
European Urology Focus
|
September 28, 2017
Characterization and Impact of TERT Promoter Region Mutations on Clinical Outcome in Renal Cell Carcinoma
Jozefina Casuscelli, Maria F Becerra, Brandon J Manley, et al.
Investigational New Drugs
|
March 11, 2017
A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel
Lillian M Smyth, Kelsey R Monson, Komal Jhaveri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 11, 2021
Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial
Meredith M Regan, Opeyemi A Jegede, Charlene M Mantia, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 30, 2020
Comprehensive Genomic Analysis of Translocation Renal Cell Carcinoma Reveals Copy-Number Variations as Drivers of Disease Progression
Julian Marcon, Renzo G DiNatale, Alejandro Sanchez, et al.
Molecular Cancer Research : MCR
|
May 27, 2021
High Response Rate and Durability Driven by HLA Genetic Diversity in Patients with Kidney Cancer Treated with Lenvatinib and Pembrolizumab
Chung-Han Lee, Renzo G DiNatale, Diego Chowell, et al.
European Urology Focus
|
July 30, 2017
Integration of Recurrent Somatic Mutations with Clinical Outcomes: A Pooled Analysis of 1049 Patients with Clear Cell Renal Cell Carcinoma
Brandon John Manley, Emily C Zabor, Jozefina Casuscelli, et al.
Science (New York, N.Y.)
|
January 6, 2018
Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma
Diana Miao, Claire A Margolis, Wenhua Gao, et al.
Page
of 15
Search research articles
Search
Showing results (111-120 of 141) with videos related to
Sort By:
Page
of 15
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 15, 2021
Prevalence and Landscape of Actionable Genomic Alterations in Renal Cell Carcinoma
Kyrollis Attalla, Renzo G DiNatale, Phillip M Rappold, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 10, 2022
Telaglenastat Plus Cabozantinib or Everolimus for Advanced or Metastatic Renal Cell Carcinoma: An Open-Label Phase I Trial
Funda Meric-Bernstam, Nizar M Tannir, Othon Iliopoulos, et al.
European Urology Focus
|
March 2, 2023
Cytoreductive Nephrectomy for Patients with Metastatic Sarcomatoid and/or Rhabdoid Renal Cell Carcinoma Treated with Immune Checkpoint Therapy
Andrew W Hahn, Ritesh R Kotecha, Paul V Viscuse, et al.
European Urology Focus
|
September 28, 2017
Characterization and Impact of TERT Promoter Region Mutations on Clinical Outcome in Renal Cell Carcinoma
Jozefina Casuscelli, Maria F Becerra, Brandon J Manley, et al.
Investigational New Drugs
|
March 11, 2017
A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel
Lillian M Smyth, Kelsey R Monson, Komal Jhaveri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 11, 2021
Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial
Meredith M Regan, Opeyemi A Jegede, Charlene M Mantia, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 30, 2020
Comprehensive Genomic Analysis of Translocation Renal Cell Carcinoma Reveals Copy-Number Variations as Drivers of Disease Progression
Julian Marcon, Renzo G DiNatale, Alejandro Sanchez, et al.
Molecular Cancer Research : MCR
|
May 27, 2021
High Response Rate and Durability Driven by HLA Genetic Diversity in Patients with Kidney Cancer Treated with Lenvatinib and Pembrolizumab
Chung-Han Lee, Renzo G DiNatale, Diego Chowell, et al.
European Urology Focus
|
July 30, 2017
Integration of Recurrent Somatic Mutations with Clinical Outcomes: A Pooled Analysis of 1049 Patients with Clear Cell Renal Cell Carcinoma
Brandon John Manley, Emily C Zabor, Jozefina Casuscelli, et al.
Science (New York, N.Y.)
|
January 6, 2018
Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma
Diana Miao, Claire A Margolis, Wenhua Gao, et al.
Page
of 15